孟德尔随机化研究表明二甲双胍治疗与多囊卵巢综合征之间不存在因果关系。
Mendelian randomization study showed no causality between metformin treatment and polycystic ovary syndrome.
作者信息
Lin Liting, Shen Huan, Wang Yanbin
机构信息
Reproductive Medical Center, Peking University People's Hospital, Peking University, Beijing, China.
出版信息
PLoS One. 2025 Apr 3;20(4):e0321380. doi: 10.1371/journal.pone.0321380. eCollection 2025.
BACKGROUND
Despite previous clinical studies providing some evidence of an association between metformin treatment and polycystic ovary syndrome(PCOS), these findings remain controversial. To investigate whether the association reflect causality, a two-sample Mendelian randomization (MR) method was conducted.
METHODS
Data from genome-wide association studies were analyzed, with the exposure factor being metformin and the outcome variable being PCOS. The inverse variance weighted(IVW) was used as the primary method for MR analysis. In addition, MR-Egger, weighted median, heterogeneity tests, and sensitivity analyses were performed.
RESULTS
The initial and validation MR analyses indicated that genetically predicted metformin treatment had no effects on PCOS. Sensitivity analyses provided additional confirmation of the reliability of the MR results.
CONCLUSIONS
Our two-sample MR analysis did not find genetic evidence supporting a significant association between metformin treatment and PCOS.
背景
尽管先前的临床研究提供了一些证据表明二甲双胍治疗与多囊卵巢综合征（PCOS）之间存在关联，但这些发现仍存在争议。为了研究这种关联是否反映因果关系，采用了两样本孟德尔随机化（MR）方法。
方法
分析了全基因组关联研究的数据，暴露因素为二甲双胍，结局变量为PCOS。逆方差加权（IVW）用作MR分析的主要方法。此外，还进行了MR-Egger、加权中位数、异质性检验和敏感性分析。
结果
初始和验证性MR分析表明，基因预测的二甲双胍治疗对PCOS没有影响。敏感性分析进一步证实了MR结果的可靠性。
结论
我们的两样本MR分析未发现支持二甲双胍治疗与PCOS之间存在显著关联的基因证据。
Zotero 插件